LifeVantage Corporation (LFVN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance is positive with revenue growth, improved gross margins, and a strong cash position. However, there are concerns about profitability due to rising expenses and seasonality affecting revenue. The Q&A reveals management's reluctance to provide specific data on LoveBiome, adding uncertainty. The dividend and share repurchase are positive, but the lack of clear guidance on LoveBiome's contribution tempers enthusiasm. Overall, the sentiment is neutral due to balanced positive and negative factors, with potential for modest stock price movement.
Key Financial Performance
Revenue $55.1 million, up 12.6% year-over-year. Growth driven by the success of the MindBody GLP-1 system and a 9.7% increase in active independent consultants in the Americas.
Revenue in the Americas $43.5 million, up 14.1% year-over-year. Growth attributed to the MindBody GLP-1 system and a 4% increase in average revenue per consultant.
Revenue in Asia Pacific and Europe $11.6 million, up 7.6% year-over-year. Growth driven by the international rollout of the MindBody system and a 13.9% increase in average revenue per consultant.
Gross Margin 79.9%, up from 79.5% in the prior year. Improvement due to lower shipping costs, favorable product mix, and lower inventory obsolescence.
Adjusted EBITDA $4.8 million, flat year-over-year. Impacted by the timing of the annual global convention.
Adjusted Non-GAAP Operating Income $2.5 million, down from $3.2 million in the prior year. Decrease due to higher variable employee compensation-related expenses and increased marketing investments.
Adjusted Non-GAAP Net Income $2.3 million or $0.17 per share, up from $1.8 million or $0.14 per share in the prior year. Increase attributed to lower income tax expense.
Cash Position $20.2 million, up from $16.9 million in the prior year. No debt reported.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MindBody GLP-1 system: Drove a 13% year-over-year revenue increase to $55.1 million. Successfully rolled out to Japan, Australia, Europe, and Thailand, contributing to international sales growth.
LoveBiome acquisition: Acquired critical assets of LoveBiome, a leader in microbiome health. LoveBiome's P84 product aligns with LifeVantage's health activation strategy. The acquisition is expected to close by mid-October 2025.
International market growth: Revenues in Asia Pacific and Europe increased by 8%, marking the first growth in 12 quarters. MindBody rollout was a key driver.
Americas market growth: Revenues increased by 14%, with a 6% rise in active accounts and a 4% increase in average revenue per consultant.
Gross margin improvement: Expanded by 40 basis points to 79.9%, driven by lower shipping costs and favorable product mix.
Shopify partnership: Entered into an agreement with Shopify to modernize technology and marketing stack, aiming for increased conversions and operational efficiency.
LoveBiome strategic acquisition: Aims to leverage LoveBiome's expertise in microbiome health and expand product offerings. Integration expected by fiscal Q2 2026.
LV360 initiatives: Laid the foundation for strategic investments and operational improvements, enabling sustainable growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Requirements: The acquisition of LoveBiome is subject to satisfactory and customary closing conditions and regulatory requirements, which could pose a risk if not met.
Integration Challenges: The integration of LoveBiome's assets and personnel into LifeVantage by the end of fiscal Q2 2026 may face operational and cultural challenges, potentially impacting the seamless transition and operational efficiency.
Foreign Currency Fluctuations: Revenue was impacted by $0.5 million due to foreign currency fluctuations, indicating a risk of continued financial impact from currency exchange rates.
Increased SG&A Expenses: Non-GAAP adjusted SG&A expenses increased significantly to $18.3 million in the fourth quarter, driven by higher variable employee compensation, global convention expenses, and marketing investments, which could pressure profitability.
Seasonality of Revenue: Revenue in the second half of fiscal 2026 is expected to be higher due to seasonality associated with the MindBody product line, which could lead to uneven financial performance throughout the year.
Supply Chain and Product Mix: While gross margin improved, it was partly due to favorable product mix and lower shipping costs. Any disruption in supply chain or unfavorable changes in product mix could negatively impact margins.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: LifeVantage expects full-year revenue for fiscal 2026 to be in the range of $225 million to $240 million. Revenue in the second half of fiscal 2026 is anticipated to be higher than the first half due to seasonality of the MindBody product line and the impact of the LoveBiome acquisition.
Adjusted Non-GAAP EBITDA: The company projects adjusted non-GAAP EBITDA to be in the range of $23 million to $26 million for fiscal 2026.
Earnings Per Share (EPS): LifeVantage anticipates adjusted non-GAAP earnings per share to be in the range of $1 to $1.15 for fiscal 2026.
Market Trends and Growth: The global gut health supplement market, which aligns with LifeVantage's product portfolio, is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a CAGR of 8.4%. This growth is expected to support the company's strategic initiatives.
LoveBiome Acquisition: The acquisition of LoveBiome is expected to close by mid-October 2025, with full integration by the end of fiscal Q2 2026. This acquisition is anticipated to accelerate growth through cross-selling opportunities and operational leverage.
Technology Modernization: LifeVantage has partnered with Shopify to modernize its technology and marketing stack, aiming to enhance customer experience, increase conversions, and support future growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Cash Dividend: On August 28, a quarterly cash dividend of $0.045 per share of common stock was announced, amounting to approximately $600,000 in total. This dividend will be paid on September 16, 2025, to stockholders of record as of September 8, 2025.
Total Value Returned to Stockholders: Since the beginning of fiscal 2024, approximately $18.6 million has been returned to stockholders through stock repurchases and dividends.
Share Repurchase Program: Approximately 160,000 shares were repurchased during the fourth quarter at an average price of $12.74 per share, totaling $2 million. As of June 30, 2025, $17.3 million remains under the existing share repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the $55 million revenue in Q4 to be at the low end of the range and $3 million below the midpoint?
A:The softness in Q4 revenue was primarily due to seasonality impacts in the U.S. market, while international markets remained strong.
Q:What is the expected growth in fiscal 2026, and how much of it will come from LoveBiome versus organic growth?
A:The company anticipates low single-digit growth in fiscal 2026, with a modest amount of revenue from LoveBiome. The exact breakdown between LoveBiome and organic growth is uncertain due to the transaction's timing and integration.
Q:Can you disclose any data on LoveBiome's sales, consultants, or its contribution to LifeVantage?
A:Management did not disclose specific revenue or consultant data for LoveBiome, stating that such information might be available later.
Q:How old is LoveBiome, and what is its market presence?
A:LoveBiome was founded in 2022, making it about 3 years old. Its largest market is the U.S., followed by Taiwan, Europe, and other countries. It has a significant footprint with some overlap with LifeVantage.
Q:What is the significance of LoveBiome's P84 product?
A:P84 is a comprehensive product focused on the gut microbiome, regulating, repairing, and restoring it. It complements LifeVantage's existing products like MindBody and pre/probiotics, with no anticipated product cannibalization. P84 ties into the GLP-1 story and is expected to have synergistic benefits when used with other products.
Q:How does LoveBiome's market presence complement LifeVantage?
A:LoveBiome's dominant footprint is on the East Coast of the U.S., complementing LifeVantage's existing footprint. The acquisition is seen as a synergistic opportunity for sustainable growth for both companies.
Q:How is P84 marketed compared to LifeVantage's MindBody and pre/probiotic products?
A:P84 is marketed as a more complete and comprehensive product targeting the microbiome itself, unlike pre/probiotics that do not directly address the microbiome. It supports gut health and enhances the effectiveness of other products like MindBody GLP-1.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue or consultant data for LoveBiome, citing that such information might be available later.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Academy Dallas
Activate event
Australia Europe
Founder CEO
GLP system
LifeVantage consultant
LoveBiome LifeVantage
MindBody GLP
Shopify
ability
acquisition
agreement asset
announcement
base
campaign
category
channel
community
company
confidence
demand
differentiation
expertise
foundation
gut health
integration
margin expansion
member LifeVantage
mid
person
plan product
project
rollout MindBody
sale industry
system LoveBiome
transaction
world
LFVN Transcript
LifeVantage Corporation (LFVN) Q3 2026 Earnings Call Transcript
Unknown5-6
The earnings call summary reveals a modest increase in revenue and EPS, with stable gross margins and slight growth in net income. However, the lack of specific strategic initiatives and forward-looking guidance, combined with a minimal decrease in gross margin, tempers enthusiasm. The absence of insights from the Q&A section and no major announcements on partnerships or shareholder returns further support a neutral sentiment. These factors suggest limited stock price movement in the short term.
LifeVantage Corporation (LFVN) Q2 2026 Earnings Call Transcript
Unknown2-4
The earnings call reflects mixed signals: declining financial performance with reduced net income and cash from operations, but optimistic guidance and strategic initiatives, including the LoveBiome acquisition and Shopify partnership. The Q&A highlighted concerns about declining sales and unclear consultant/customer metrics. The positive aspects, like new product launches and market expansion, are balanced by financial challenges, leading to a neutral sentiment. Without market cap data, the stock's sensitivity to these mixed signals remains uncertain, suggesting a neutral impact over the next two weeks.
LifeVantage Corporation (LFVN) Q1 2026 Earnings Call Transcript
Unknown11-4
The earnings call reveals mixed signals: a slight revenue increase and positive net income growth, but declining margins and cash position raise concerns. The LoveBiome acquisition and technology partnership with Shopify offer growth potential, yet integration risks and competitive pressures persist. The Q&A session didn't reveal major red flags, but the market's reaction to integration progress remains uncertain. The dividend and share repurchase plan provide some support, but overall, the outlook remains balanced with no strong catalysts for significant stock movement.
LifeVantage Corporation (LFVN) Q4 2025 Earnings Call Transcript
Unknown9-4
The earnings call presents mixed signals. Financial performance is positive with revenue growth, improved gross margins, and a strong cash position. However, there are concerns about profitability due to rising expenses and seasonality affecting revenue. The Q&A reveals management's reluctance to provide specific data on LoveBiome, adding uncertainty. The dividend and share repurchase are positive, but the lack of clear guidance on LoveBiome's contribution tempers enthusiasm. Overall, the sentiment is neutral due to balanced positive and negative factors, with potential for modest stock price movement.
LFVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
